Suven to present positive Preclinical, Phase-1 clinical data of advanced molecules at Sleep 2018

01 Jun 2018 Evaluate

Suven Life Sciences (Suven) will participate and present positive Preclinical and Phase-1 clinical data of advanced molecules from their portfolio of new chemical entities (NCEs) at Sleep 2018, A Joint Meeting of The American Academy of Sleep Medicine and The Sleep Research Society being held at Baltimore, MD, USA during June 2-6, 2018.

SLEEP is the premier world forum to present and discuss the latest developments in clinical sleep medicine and sleep and circadian science.

The SLEEP meeting provides evidence-based education to advance the science and clinical practice of sleep medicine, disseminates cutting-edge sleep and circadian research, promotes the translation of basic science into clinical practice.

During the conference Suven will present their Phase 2 ready differentiated Clinical stage therapeutic candidate SUVN-G3031 (Histamine-3 receptor antagonist) for the treatment of Narcolepsy and Narcolepsy associated with Cataplexy. Narcolepsy is a commercially attractive space with a large unmet need. The data presentation highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.


Suven Life Sciences Share Price

133.50 -3.40 (-2.48%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×